I can extract side effects.

Chapter 24 Choosing a Cooperation Plan
The Hilton Hotel in Kuncheng was almost reserved by representatives of global pharmaceutical giants and large domestic pharmaceutical companies.

In the past few days, medical representatives have come in and out of the hotel, meeting countless colleagues every day.

Everyone was smiling when they met, but looking back, they were secretly inquiring about the plans of other colleagues, and at the same time, by judging the expressions of the other party, they speculated whether there was any real progress in the negotiation with Sanqing Pharmaceutical.

The people of Sanqing Pharmaceutical Co., Ltd. deal with the people of the pharmaceutical company with smiles every day, their mouths are so dry that their faces are stiff with laughter.

But everyone is full of energy, proud and elated, with endless energy all over their bodies.

Wei Kang has not been idle for the past few days. He discussed with Sun Chengren that Sanqing Pharmaceuticals needs a strong sales channel in addition to funds if it wants to develop rapidly.

This channel includes not only the domestic market, but also the channels for drugs to be marketed abroad.

The domestic channels are good. Sanqing Pharmaceutical has been established for many years and has already established its own sales system. There is no problem in the development of domestic market channels.

Moreover, this new anti-cancer drug fills the gap in the field of new drug research and development in China, and it will definitely receive support from the state, and its future launch will be smooth.

However, Sanqing Pharmaceutical is a small pharmaceutical company after all, without foreign sales channels, and it is difficult to establish and improve it by itself in just a few years.

For those top big pharmaceutical companies, there are many ways they can adopt if they want to enter the market of a country, whether it is a sole proprietorship or a joint venture to build a factory, or cooperate with a local company, it is simple and easy .

Through these simple methods, they can quickly expand sales channels in a country without too much obstruction.

For international pharmaceutical giants such as Pfizer, Bayer, and Johnson & Johnson, they not only have abundant funds, but also have top-notch resources and contacts in various countries, and their sales channels have been established long ago.

They can make a drug enter dozens or even hundreds of countries' hospitals, clinics, pharmacies and other medical institutions in the shortest time and effortlessly.

And they don't need to pay too much for marketing and publicity. Their own brand alone is the guarantee of curative effect, and they can gain the trust of patients and actively choose their medicines.

Patients not only believe in the efficacy of top pharmaceutical companies, but more importantly, if there is a problem, they can also get sky-high compensation from them.

Such reputation is even more important than curative effect.

Just like Pfizer, it once received the largest fine in the history of a single company, broke a world record, and left giants in other industries far behind.

In 2009, Pfizer paid $23 billion to settle lawsuits accused of improperly marketing and concealing potential adverse effects of a blockbuster drug, Bextra.

This is the fourth time that Pfizer has been punished for the same reason, and almost all global pharmaceutical companies have encountered accusations in this regard.

Therefore, if people will continue to trust pharmaceutical giants such as Pfizer in the future, it is only because of the higher and higher fines.

After all, even the largest fine in the world is worth only three weeks of Pfizer's sales.

People like to believe that even if something goes wrong with a big brand drug, they can receive a high enough compensation.

This is an advantage that other companies cannot match.

Therefore, for Sanqing, cooperation is the fastest way to make money, and it can also continuously expand its own assets and enhance brand awareness in the shortest time.

But how to cooperate is also what Weikang needs to measure.

In the past few days, the cooperation applications of all pharmaceutical companies have been submitted, and each pharmaceutical company has several quotations.

Cooperative development, buyout at a fixed price, and the overall acquisition of Sanqing Pharmaceutical, including all assets such as drug research and development laboratories.

These pharmaceutical companies are still unwilling to give up and offer high prices for buyouts and acquisitions in an attempt to impress Weikang.

Especially the prices offered by the multinational giants are more and more ruthless.

Wei Kang did not expect that Bayer could offer a price of 100 billion euros.

When Sun Chengren saw the price on the plan, he couldn't help shaking his hands.

"Uncle Sun, is this price tempting?"

"100 billion, it's still euros. If you sell it, you can retire directly, and you don't have to worry about it in your next life."

Old Sun rubbed his chest, nodded and said: "It would be a lie to say that I am not tempted. My heart almost stopped suddenly when I saw this number. And the price can definitely be negotiated again. If Sanqing's major shareholder is me, I will I definitely agreed, anyway, I am almost 50, and it is not a loss to retire directly at my age."

"But I understand you. You definitely want to make Sanqing bigger and stronger, and make China's national pride. Career is more important to you than money. Otherwise, when you were about to go bankrupt, you would have sold Sanqing a long time ago. Cleared."

"Haha, it's still Uncle Sun who understands me. It's no wonder he was the one who watched me grow up."

Wei Kang smiled happily: "However, don't worry, it's only 100 billion. It's nothing more than the difference between getting it now and getting it in two years."

"Moreover, this price must have been leaked, and the cooperation conditions of other pharmaceutical companies will not be too far behind."

This is true. This price has persuaded most pharmaceutical companies to retreat. After all, 100 billion euros is not something that ordinary pharmaceutical companies can afford.

Wei Kang continued: "I have already decided, the main thing is to discuss cooperation with multinational giants, it is impossible to sell."

"But in terms of cooperation, I prefer long-term cooperation, but they are definitely unwilling to give up the initiative, so this is a difficult negotiation process. You have to shop around and try to choose a sincere partner."

"At present, there are three options available. The first one is equity investment cooperation, directly investing in the anti-cancer drug project and participating in the follow-up development, but generally this is more suitable in the early stage of new drug research and development, and we have already produced results. If we let Giving out shares is equivalent to handing over, so this is excluded."

"The second type of agency cooperation, we provide overseas agency rights for finished drugs, and they are responsible for subsequent development after importing, even if they sell under their own brand under a different name, and then we get a sales commission. This method has a high degree of freedom. , it is logically the best way, but unfortunately Sanqing is too weak and does not have enough production capacity, it seems that we can only consider it later."

"The third is authorized cooperation. We will soon be able to receive a large amount of advance payment to alleviate the urgent need, and we will continue to have income in the future. Although the total amount is limited, it can greatly promote the rapid growth of the company. This plan is currently the most suits us."

"However, this plan also has different conditions. It still depends on the depth of cooperation between the two parties. If we can reach a strategic cooperation with a certain giant and develop overseas markets together, this plan is the best."

"So we still have to have a good discussion with each giant and strive for the best conditions before we can finally make a decision."

Old Sun said with relief: "It seems that Mr. Wei has thought very clearly, and I also agree with your thoughts very much."

Wei Kang put down the report in his hand and said, "Then let's talk according to this standard. As for the domestic pharmaceutical companies, I'll take a look at their discarded prescriptions first. If there are good ones, I can't give them up. It's best to buy them. Since they have done a good job The gift is prepared, and I don’t think I would mind packing it up and selling it to us at a cheaper price.”

"You! Why did you become so superstitious all of a sudden?" Old Sun shook his head with a laugh.

Wei Kang scratched his head and smiled: "Isn't this a fluke mentality caused by the deviation of survivors? Who doesn't have a special preference?"

The two discussed some details further, and Lao Sun left.

Wei Kang was lost in thought.

The desk in front of him is neatly filled with the cooperation plans of major pharmaceutical companies.

He reached out to pick up the plans of three international pharmaceutical companies, namely Pfizer, Bayer and Johnson & Johnson.

The plans of these three companies are currently the most convincing, but which one to choose in the end.

It still depends on the sincerity of the other party.

The choice is in his hands.

(End of this chapter)